Managing Gastrointestinal Stromal Tumors with Imatinib
Author Information
Author(s): Ravindra S Date, Nicholas A Stylianides, Kishore G Pursnani, Jeremy B Ward, Muntzer M Mughal
Primary Institution: Department of Gastrointestinal Surgery, Lancashire Teaching Hospital NHS Foundation Trust
Hypothesis
How can Imatinib improve the management of gastrointestinal stromal tumors (GIST)?
Conclusion
Most GISTs can be managed effectively using existing protocols, but further research is needed for specific management situations.
Supporting Evidence
- Surgical resection has a 5-year survival rate of 28-35%.
- Imatinib has improved outcomes in metastatic and unresectable GIST.
- Current guidelines are clear for managing unresectable and metastatic GIST.
Takeaway
Doctors can treat most stomach tumors called GISTs with surgery and a medicine called Imatinib, but they need to learn more about some tricky cases.
Methodology
A case note study of patients diagnosed with GIST from a prospectively kept database.
Limitations
The study had a small sample size and did not apply any statistics to the data.
Participant Demographics
Median age was 66 years, with a male to female ratio of 9:7.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website